Lates News

On August 26, Ding Medicine announced on the Hong Kong Stock Exchange that the net revenue of its products in the first half of the year increased by 15% to 215 million US dollars compared to the same period last year; research and development expenses decreased by 4% to 111 million US dollars; the net loss decreased by 44.6 million US dollars to 89.2 million US dollars compared to the same period last year mainly due to revenue growth outpacing net operating expenses; basic and diluted loss per share was 0.08 US dollars.